High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

Mov Disord. 1996 May;11(3):327-9. doi: 10.1002/mds.870110319.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects*
  • Carbidopa / administration & dosage
  • Carbidopa / adverse effects
  • Dopamine Agonists / administration & dosage*
  • Dopamine Agonists / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced / diagnosis
  • Dyskinesia, Drug-Induced / drug therapy*
  • Female
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / adverse effects*
  • Male
  • Middle Aged
  • Neurologic Examination / drug effects
  • Parkinson Disease / drug therapy*
  • Pergolide / administration & dosage*
  • Pergolide / adverse effects

Substances

  • Antiparkinson Agents
  • Dopamine Agonists
  • Pergolide
  • Levodopa
  • Carbidopa